Both GTS-21 itself and its demethylated active metabolite 4-OH-GTS-21 display nootropic and neuroprotective effects, and GTS-21 is being investigated for the treatment of Alzheimer's disease, nicotine dependence, and, most significantly, for schizophrenia.
GTS-21 i njegov demetilisani aktivni metabolit 4-OH-GTS-21 manifestuju nootropne i neuroprotektivne efekte, i GTS-21 se ispituje za moguću primenu u tretmanu Alchajmerove bolesti, nikotinske zavisnosti, kao i šizofrenije.